US Stock MarketDetailed Quotes
VYGR Voyager Therapeutics
- 5.655
- +0.225+4.14%
Close Nov 22 16:00 ET
- 5.560
- -0.095-1.68%
Post 20:01 ET
308.91MMarket Cap8.57P/E (TTM)
5.720High5.410Low359.89KVolume5.490Open5.430Pre Close2.02MTurnover0.99%Turnover Ratio1.90P/E (Static)54.63MShares11.72052wk High0.94P/B205.44MFloat Cap5.19052wk Low--Dividend TTM36.33MShs Float31.910Historical High--Div YieldTTM5.71%Amplitude2.460Historical Low5.620Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Voyager Therapeutics Stock Forum
Very oversold, less than 1% profitable positions, undervalued by all except p/e which is still under market avg.
This was over $10 recently, and earnings were great, except Wall St was scared of recession at the time. I'm guessing once they are satisfied, this will go back up
Dow Jones· 2 mins ago
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Voyager to receive upfront consideration of $15 million and is eligible to receive up to $305 million in potential associated milestone payments and royalties
Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Voyager Therapeutics (Nasdaq: VYGR) has announced a new license agreement with Novartis AG (NYSE: NVS) for a novel capsid from Voyager's TRACER™ capsid discovery platform. The capsid will be used in a gene therapy program targeting an undisclosed rare neurologic disease. This agreement expands Voyager's partnered portfolio of TRACER-enabl...
Looks like 6 holds the big buy but we shall see. Don't expect it to get much lower.
Voyager Therapeutics Says First Participants Dosed In Single Ascending Dose Trial of VY-TAU01 For Treatment Of Alzheimer's Disease
No comment yet